Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
Issues And Trends In Healthcare Delivery System01:29

Issues And Trends In Healthcare Delivery System

The issues and trends in healthcare delivery are constantly changing. The COVID-19 pandemic is one recent issue that wreaked havoc on healthcare systems, causing a shortage of healthcare workers, high demand for medicines and supplies, and increased medical expenditure due to a lack of insurance. Other issues include rising healthcare costs and care fragmentation.
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Medicine and Art at IMA and IMAJ.

The Israel Medical Association journal : IMAJ·2024
Same author

Priority setting for health technology adoption at the national level: Lessons learned over 25 years' experience.

International journal of technology assessment in health care·2023
Same author

Less Is More (Healthy): Overuse of Healthcare Services.

The Israel Medical Association journal : IMAJ·2022
Same author

Benefit versus risk of chromosomal microarray analysis performed in pregnancies with normal and positive prenatal screening results: A retrospective study.

PloS one·2021
Same author

[Living with an ongoing crisis - insights from the coronavirus - SARS-CoV].

Harefuah·2020
Same author

The 20th anniversary of IMAJ.

The Israel Medical Association journal : IMAJ·2019

Related Experiment Video

Updated: May 31, 2026

Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease Stages
08:26

Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease Stages

Published on: February 23, 2024

[Personalized medicine--the future is already here].

Ifat Abadi-Korek, Joshua Shemer

    Harefuah
    |June 18, 2011
    PubMed
    Summary

    Identifying K-ras mutations in colorectal cancer (CRC) patients is crucial for personalized medicine. This study assessed K-ras mutation prevalence in stage IV CRC, informing targeted therapy selection and improving patient outcomes.

    Area of Science:

    • Oncology
    • Genetics
    • Personalized Medicine

    Background:

    • Colorectal cancer (CRC) treatment increasingly relies on targeted therapies.
    • Epidermal Growth Factor Receptor (EGFR) inhibitors like cetuximab are key treatments for CRC.
    • K-ras mutations predict resistance to EGFR inhibitors, making K-ras testing essential for treatment selection.

    Discussion:

    • This study evaluated K-ras mutation prevalence in stage IV CRC patients who had failed prior treatments.
    • The observed mutation patterns align with findings from other international studies.
    • The findings underscore the importance of K-ras testing for personalized medicine in CRC.

    Key Insights:

    • K-ras mutation status is a critical biomarker for selecting appropriate EGFR-targeted therapies in colorectal cancer.

    More Related Videos

    Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
    10:28

    Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

    Published on: July 24, 2019

    Related Experiment Videos

    Last Updated: May 31, 2026

    Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease Stages
    08:26

    Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease Stages

    Published on: February 23, 2024

    Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
    10:28

    Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

    Published on: July 24, 2019

  • Prevalence of specific K-ras mutations in Israeli stage IV CRC patients was characterized.
  • Personalized medicine approaches, guided by genetic testing, enhance treatment efficacy.

    • Outlook:

    • Promoting the understanding and adoption of personalized medicine in the Israeli healthcare system is vital.
    • Integrating genetic testing into routine clinical practice can optimize CRC treatment strategies.
    • Personalized medicine holds the potential to improve patient health outcomes and reduce healthcare costs.